(Total Views: 974)
Posted On: 11/16/2020 2:54:09 PM
Post# of 154912
Two points I would add regarding Brian Brothen
1) he started in July of 2020 so he is a relatively new employee who was likely just ramping up as we were finishing interim enrollment
2) according to his resume he has a good deal of oncology/biotech sales experience which may make him an ideal go between between MDs at trial sites and the company
His LinkedIn profile
https://www.linkedin.com/in/brian-brothen/
So although I agree he isn't a "trial enrollment guy" I think we can't ignore that he has a good deal of experience gently nudging MDs to move deals along in the oncology space. That seems very similar to what he is now doing with the trial sites for CytoDyn.
1) he started in July of 2020 so he is a relatively new employee who was likely just ramping up as we were finishing interim enrollment
2) according to his resume he has a good deal of oncology/biotech sales experience which may make him an ideal go between between MDs at trial sites and the company
His LinkedIn profile
https://www.linkedin.com/in/brian-brothen/
So although I agree he isn't a "trial enrollment guy" I think we can't ignore that he has a good deal of experience gently nudging MDs to move deals along in the oncology space. That seems very similar to what he is now doing with the trial sites for CytoDyn.
(9)
(0)
